Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Keytruda

- PMLiVE

GSK gains rights to Hansoh’s ADC candidate in deal worth more than $1.7bn

HS-20093 is being developed for a range of solid tumour types, including lung cancer

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

EU flag

EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

Merck and Owkin collaborate to develop AI-powered diagnostics for cancer

The companies aim to develop a pre-screening test to improve MSI-H testing for cancer

- PMLiVE

Merck’s Keytruda approved by EC for two new gastrointestinal cancer indications

Both approvals follow recommendations from the European Medicines Agency’s human medicines committee

- PMLiVE

EC, HMA and EMA publish first version of Union list of critical medicines

The established list aims to prevent potential future shortages of critical medicines in the EU

- PMLiVE

Astellas’ menopause drug granted EC approval to treat vasomotor symptoms

More than half of women aged 40 to 64 years experience symptoms such as hot flashes

EU flag

EC approves Blueprint’s Ayvakyt as first treatment for rare haematological disorder

The therapy targets the primary underlying cause of indolent systemic mastocytosis

- PMLiVE

GSK’s Jemperli combination receives EC approval for endometrial cancer

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

Merck shares positive phase 3 results for investigational pneumococcal vaccine in adults

V116 is designed to address the strains responsible for adult pneumococcal disease

- PMLiVE

Merck receives FDA approval for Keytruda combination in gastric cancer

An estimated 26,500 people in the US will be diagnosed with gastric cancer in 2023

- PMLiVE

Almirall granted EC approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links